BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 31, 2018--
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will report third quarter ended September 30, 2018
financial results on Wednesday, November 7, 2018. Following distribution
of the earnings release via wire services, the Ocular Therapeutix
management team will host a live conference call and webcast at 4:30
p.m. Eastern Time to review the Company’s financial results and provide
a general business update.
The live webcast can be accessed by visiting the Investors section of
the Company’s website at investors.ocutx.com.
Please connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to access the
webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765)
507-2620 (International) to listen to the live conference call. The
conference ID number for the live call will be 7997646. An archive of
the webcast will be available until March 8, 2019 on the Company’s
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s lead product candidate, DEXTENZA®
(dexamethasone insert), has completed Phase 3 clinical development for
the treatment of ocular pain and inflammation following ophthalmic
surgery. The New Drug Application (NDA) for DEXTENZA has a target action
date under the FDA Prescription Drug User Fee Act (PDUFA) of December
28, 2018. OTX-TP (travoprost insert) is an intracanalicular insert in
Phase 3 clinical development for the reduction of intraocular pressure
in patients with primary open-angle glaucoma and ocular hypertension.
The Company’s earlier stage assets include OTX-TIC, an extended-delivery
travoprost intracameral implant for the reduction of intraocular
pressure in patients with glaucoma and ocular hypertension, as well as
sustained release intravitreal implants for the treatment of retinal
diseases. These intravitreal implants include the development of
OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with
Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular
endothelial growth factor (VEGF) trap. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal
incisions following cataract surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181031005135/en/
Source: Ocular Therapeutix, Inc.
Senior Vice President, Commercial